PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Axsome Therapeutics Inc | AXSM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.34 | -0.38% | 90.00 | 90.45 | 89.00 | 90.08 | 90.34 | 09:37:47 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 89.97 | 90.40 | 0.43 | 0.48% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 411 | 38,336 | $ 89.98 | $ 3,449,362 | 1,774,458 | 7.63 - 121.06 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:37:46 | 250 | $ 90.00 | USD |
Axsome Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 3.33B | 37.02M | $ -30.97M | -1.14 | - | 36.23M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Axsome Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/13/2020 | 06:52 | Dow Jones News | Axsome Inks License Pact With Pfizer on Narcolepsy,.. |
| 1/13/2020 | 06:00 | GlobeNewswire Inc. | Axsome Therapeutics Enters into Exclusive License Agreement.. |
| 12/30/2019 | 06:15 | GlobeNewswire Inc. | Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and.. |
| 12/23/2019 | 16:19 | GlobeNewswire Inc. | Axsome Therapeutics Announces Closing of $200 Million Public.. |
| 12/19/2019 | 07:05 | GlobeNewswire Inc. | Axsome Therapeutics Announces Pricing of Public Offering of.. |
| 12/18/2019 | 16:01 | GlobeNewswire Inc. | Axsome Therapeutics Announces Proposed Public Offering of.. |
| 12/17/2019 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics Added to NASDAQ Biotechnology Index |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXSM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 88.34 | 93.50 | 86.10 | 90.99 | 593,517 | 1.66 | 1.88% |
| 1 Month | 98.51 | 121.06 | 85.10 | 96.10 | 1,126,252 | -8.51 | -8.64% |
| 3 Months | 22.87 | 121.06 | 20.48 | 68.16 | 1,543,976 | 67.13 | 293.53% |
| 6 Months | 25.10 | 121.06 | 13.64 | 49.57 | 1,161,151 | 64.90 | 258.57% |
| 1 Year | 8.00 | 121.06 | 7.63 | 33.81 | 1,164,478 | 82.00 | 1,025.0% |
| 3 Years | 4.90 | 121.06 | 1.94 | 22.08 | 668,456 | 85.10 | 1,736.73% |
| 5 Years | 9.00 | 121.06 | 1.94 | 21.80 | 490,839 | 81.00 | 900.0% |
Axsome Therapeutics Description
| Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development. |
